These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

858 related articles for article (PubMed ID: 21923596)

  • 1. Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.
    Boruah PK; Bolesta S; Shetty SM
    Pharmacotherapy; 2011 Sep; 31(9):925. PubMed ID: 21923596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options.
    Allegra A; Alonci A; Penna G; Russo S; Gerace D; Greve B; D'Angelo A; Catena S; Musolino C
    Hematol Oncol; 2012 Mar; 30(1):41-5. PubMed ID: 21702057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.
    Wäsch R; Jakob T; Technau K; Finke J; Engelhardt M
    Ann Hematol; 2012 Feb; 91(2):287-9. PubMed ID: 21494796
    [No Abstract]   [Full Text] [Related]  

  • 4. Lenalidomide-induced interstitial lung disease.
    Chen Y; Kiatsimkul P; Nugent K; Raj R
    Pharmacotherapy; 2010 Mar; 30(3):325. PubMed ID: 20180616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients.
    Castaneda CP; Brandenburg NA; Bwire R; Burton GH; Zeldis JB
    J Clin Oncol; 2009 Jan; 27(1):156-7. PubMed ID: 19047275
    [No Abstract]   [Full Text] [Related]  

  • 7. Fatal toxic epidermal necrolysis associated with minoxidil.
    Karaoui LR; Chahine-Chakhtoura C
    Pharmacotherapy; 2009 Apr; 29(4):460-7. PubMed ID: 19323621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term complete remission in a multiple myeloma patient after Stevens-Johnson syndrome due to lenalidomide therapy.
    Musolino C; Alonci A; Catena S; Rizzotti P; Russo S; Rotondo F; Allegra A
    Acta Oncol; 2013 Jun; 52(5):1050-1. PubMed ID: 23113590
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of Stevens-Johnson syndrome.
    Crosby SS; Murray KM; Marvin JA; Heimbach DM; Tartaglione TA
    Clin Pharm; 1986 Aug; 5(8):682-9. PubMed ID: 3742953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stevens-Johnson syndrome as an unusual adverse effect of azithromycin.
    Brkljacić N; Gracin S; Prkacin I; Sabljar-Matovinović M; Mrzljak A; Nemet Z
    Acta Dermatovenerol Croat; 2006; 14(1):40-5. PubMed ID: 16603101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
    Dasanu CA; Alexandrescu DT
    Eur J Haematol; 2009 Mar; 82(3):231-4. PubMed ID: 19018868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 2-year-old girl with Stevens--Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin.
    Arca E; Köse O; Erbil AH; Nişanci M; Akar A; Gür AR
    Pediatr Dermatol; 2005; 22(4):317-20. PubMed ID: 16060867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide: Stevens-Johnson syndrome.
    Prescrire Int; 2010 Jun; 19(107):125. PubMed ID: 20740722
    [No Abstract]   [Full Text] [Related]  

  • 14. Neutrophilic dermatosis complicating lenalidomide therapy.
    Thieu KP; Rosenbach M; Xu X; Kist JM
    J Am Acad Dermatol; 2009 Oct; 61(4):709-10. PubMed ID: 19577327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
    Sviggum HP; Davis MD; Rajkumar SV; Dispenzieri A
    Arch Dermatol; 2006 Oct; 142(10):1298-302. PubMed ID: 17043184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
    Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
    Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of lenalidomide-induced hypersensitivity pneumonitis.
    Lerch E; Györik S; Feilchenfeldt J; Mazzucchelli L; Quadri F
    Onkologie; 2010; 33(5):249-52. PubMed ID: 20502059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant thrombomodulin improved Stevens-Johnson syndrome with high serum high-mobility group-B1 DNA-binding protein induced by lenalidomide administered to treat multiple myeloma.
    Inoue Y; Saito T; Tsuruoka Y; Sato K; Nishio Y; Suzuki Y; Kato M; Isobe Y; Sakai H; Takahashi M; Miura I
    Thromb Res; 2013 Oct; 132(4):493-4. PubMed ID: 24050827
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 43.